Peter Verhamme retweeted
Ik post niet snel dingen die ik op televisie heb verteld, maar deze tussenkomst in #DeTafel over @EricMuraille wil ik echt met u delen. Reacties welkom.
Peter Verhamme retweeted
We came together today with one clear objective: find a credible and immediate solution to #Ukraine’s financing needs.
A victory for Ukraine, for Europe, for financial stability and for international law.
➖ 🇧🇪 Prime minister @Bart_DeWever after the European Council #EUCO
Peter Verhamme retweeted
Human genetic data suggest a link between thromboembolic pathways and long COVID 🩸
Happy to see our study published today in @NatureCVR: nature.com/articles/s44161-0…
Super-thanks to @VerhammePeter, @AndreasVerstrae, @t_vanassche, @KathleenFreson, and many many more!
Peter Verhamme retweeted
#Multi -Gene Panel for #Thrombophilia Testing in Venous Thromboembolism jthjournal.org/article/S1538…
Peter Verhamme retweeted
Great presentations from #andreasVerstraete & @artschuermans at BSTH2024 meeting today ! Congrats Andreas for winning the PaulCapel price for clinical research 🎉🍾 @CMVB_KULeuven @Cardio_KULeuven
Peter Verhamme retweeted
Is FXI inhibition the future of the management of cancer-associated thrombosis?
Dr. @MarcelloDiNisio provided an elegant review @ICTHIC
Potentially low risk of bleeding, less drug-drug interactions, less dependence on renal/liver for elimination.
Phase 3 trials on-going! Stay tuned :)
Peter Verhamme retweeted
📢Publication alert! #Annexa-I, the first-ever RCT of #andexanet in patients with intracranial bleeding who are using FXa inhibitors. What are your thoughts of the risk/benefit balance?
The factor Xa inhibitor reversal agent andexanet reduced expansion of intracerebral hemorrhages caused by factor Xa inhibitors but resulted in more thrombotic events than usual care. Read the full ANNEXA-I trial results: nej.md/3wAoERb
Peter Verhamme retweeted
nature.com/articles/s41591-0… Not only an issue in the UK, but also in Belgium and many other countries. We desperately need dedicated programs that provide long-term #funding and targeted #support to allow trainee #clinician–#scientists to establish their careers and flourish!
Prof. Saskia Middeldorp at the BSTH presenting High-Low and Alife-2. Practice changing! @MiddeldorpS
Peter Verhamme retweeted
Nog geen twee eeuwen geleden vormden Nederland, België en Luxemburg één staat. In 1830 viel het koninkrijk uiteen en kreeg Nederland er een nieuw buurland bij: België. Maar wat gebeurde er? In dit boek (verschijnt 19/10) wordt een reconstructie geboden van de periode 1815-1839.
Peter Verhamme retweeted
The @CMVB_KULeuven is leaving for #isth2023 meeting !!!! Our PhD students have 5 oral and 3 poster presentations 🤩🤩
I'm thrilled to welcome everyone to #ISTH2023 in beautiful #Montreal starting on the 24th! 🌟 Get ready for an amazing exchange of knowledge, collaboration and inspiration. Let's push the boundaries of science together! 🚀🔬 #MedEd #ScienceUnleashed
Peter Verhamme retweeted
Very honored with this RPTH Editor's Award! Many thanks to all colleagues and participating centers for their efforts in challenging times! @t_vanassche @VerhammePeter @UZLeuven @gzaziekenhuizen @ZOLziekenhuis
🎉We're pleased to announce 3 early career researchers as the latest recipients of our Editor's Awards: @MatthiasEngelen, @Tessa_Noorder and Jie Sun. Learn more and read their award-winning work here: isth.org/news/634715/RPTH-an…
Peter Verhamme retweeted
As the short month of February draws to a close, enjoying a final day of our cover selection at @atvbahajournals, for our study on #neutrophils in S. aureus-driven infective #endocarditis. https://nitter.cf/t.co/AWTJLMlmeI
A milestone!
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial thelancet.com/journals/lance…
6
Peter Verhamme retweeted
We felt it unbearable that #pregnant women with #thrombosis #pulmonaryembolism use #LMWH doses tested in elderly. We took the challenge and did a #RCT to find out. Stay tuned for more news on the Highlow study! @fniainle @RodgerMarc @VerhammePeter @INVENT_VTE @INNOVTE1
More acquired hemophilia after COVID (vaccination) ?
In this case report, acquired #hemophilia A was diagnosed 10 days after #AstraZeneca #COVID19 vaccination in a man with autoimmune disease. The authors note that causality is uncertain, since AHA reports remain scarce despite billions of vaccinations.
https://nitter.cf/t.co/TpJD36hKDJ
Another beautiful day of science. #expert_pe2022 @Erik_Klok_MD
Our fantastic hosts for the next 2 days…
Dear participants and faculty of #expert_pe2022, welcome to Leiden! Thrilled to see you all.
3








































